DLA PIPER LLP (US)

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association of innovative biopharmaceutical research companies.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

S 832
EPIC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 6

Pharmacy

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Health Issues

S. 832, EPIC Act of 2025.

Medicare/Medicaid

Medicare policies.

Budget/Appropriations

H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.

Defense

National security issues related to pharmaceutical industry, including supply chain.

Trade (domestic/foreign)

Trade policies and agreements, including IP protections, and administrative tariff actions.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.